. 2014 Oct 2;7:86. doi: 10.1186/s13048-014-0086-2

Table 1.

Summary of clear cell adenocarcinoma of the peritoneum

Case	Authors	Age	Tumor size and location	Past history or concurrent disease	Concurrent endometriosis	Treatment	Residual tumour	Outcome
1	Evans et al. [3]	54	18×13 cm	Both Ov EM, AM, EH	Yes	DS followed by RT (pelvic; 4500R,upper abdomen;3000 R)	None	NA
1	Evans et al. [3]	54	sigmoid mesocolon	Both Ov EM, AM, EH	Yes	DS followed by RT (pelvic; 4500R,upper abdomen;3000 R)	None	NA
2	Lee et al. [4]	67	6 cm	Concurrent EMA G1 of Ut (stageIb)	No	DS+TAH+BSO	>2 cm	NA
2	Lee et al. [4]	67	Pelvic	Concurrent EMA G1 of Ut (stageIb)	No	DS+TAH+BSO	>2 cm	NA
3	Tziortzioti et al. [5]	62	0.5-2 cm	Concurrent CCC in EP	No	DS+TAH+BSO +OM followed by CHT (6 cycles, regimen NA)	>2 cm	DOD at 6 mo
3	Tziortzioti et al. [5]	62	Peritoneal and omental	Concurrent CCC in EP	No	DS+TAH+BSO +OM followed by CHT (6 cycles, regimen NA)	>2 cm	DOD at 6 mo
4	Ichimura et al. [6]	45	NA	Both Ov EM	Yes	DS+TAH+BSO followed by CHT (3 cycles of CPA,CDDP, CBDCA)	None	ROD at 32 mo
4	Ichimura et al. [6]	45	Pelvic	Both Ov EM	Yes	DS+TAH+BSO followed by CHT (3 cycles of CPA,CDDP, CBDCA)	None	ROD at 32 mo
5	Hama et al. [7]	53	NA	EM	Yes	DS+BSO followed by CHT (regimen NA)	>2 cm	DOD at 5 mo
5	Hama et al. [7]	53	Ascites and small peritoneal solid lesions	EM	Yes	DS+BSO followed by CHT (regimen NA)	>2 cm	DOD at 5 mo
6	Terada et al. [8]	49	3 cm, 2 cm	Past EMA G3 of Ut (TAH+BSO)	No	DS	None	NED at 6 mo
6	Terada et al. [8]	49	Gastric peritoneal, splenic hilus	Past EMA G3 of Ut (TAH+BSO)	No	DS	None	NED at 6 mo
7	Takano et al. [9]	53	5 cm	None	No	DS followed by CHT (1 cycle of CPT-11,CDDP, 1 cycle of TC)	>2 cm	DOD at 5 mo
7	Takano et al. [9]	53	Upper abdomen between liver and diaphragm and omentum	None	No	DS followed by CHT (1 cycle of CPT-11,CDDP, 1 cycle of TC)	>2 cm	DOD at 5 mo
8	Takano et al. [9]	66	15×20 cm	None	No	DS+TAH+BSO+OM+PLD+PAD followed by CHT (6 cycles of CPT-11, CDDP)	None	NED at 20 mo
8	Takano et al. [9]	66	Infracolic omentum and peritoneum of right abdominal wall	None	No		None	NED at 20 mo
9	Matsuo et al. [10]	37	14×13 cm	EM	Yes	DS followed by CHT (6 cycles of TC), Secondary devulking surgery	None	ROD at 18 mo
9	Matsuo et al. [10]	37	Abdominal scar of EM surgery	EM	Yes		None	ROD at 18 mo
10	Muezzinoglu et al. [11]	54	25 cm	Peritoneal EM	Yes	DS+TAH+BSO following by CHT (regimen NA)	None	NED at 12 mo
10	Muezzinoglu et al. [11]	54	Abdominal	Peritoneal EM	Yes	DS+TAH+BSO following by CHT (regimen NA)	None	NED at 12 mo
11	Johnson et al. [12]	54	5.6×3.7×3.5 cm	3xMMs, TAH+BSO for LM and menorrhagia	No	CHT (6 cycles of TC) followed by EBR followed by the interstitial HDR BT boost	<2 cm	ROD at 4 mo
11	Johnson et al. [12]	54	proximal vagina and vaginal cuff	3xMMs, TAH+BSO for LM and menorrhagia	No		<2 cm	ROD at 4 mo
12	This report	59	7 cm	AM, EM	Yes	DS+TAH+BSO+PLD followed by CHT (6 cycles of TC)	None	NED at 5 mo
12	This report	59	Pelvic (pouch of douglas)	AM, EM	Yes	DS+TAH+BSO+PLD followed by CHT (6 cycles of TC)	None	NED at 5 mo

EM, endometriosis; Ov, ovary; Ut, uterus; AM, adenomyosis); EH, endometrial hyperplasia; EP, endometrial polyp; LM, leiomyoma; EMA, endometrial adenocarcinoma; CCC, clear cell adenocarcinoma, MM, myomectomy; DS, debulking surgery; PLD, pelvic lymph node dissection; PAD, para-aortic lymph node dissection; OM, omentectomy; CHT, chemotherapy; RT, radiotherapy; EBR, external beam radiotherapy; BT, brachytherapy; CPT-11, irinotecan hydrochloride; CDD, cisplatin; CBDCA, carboplatin; CPA, cyclophosphamide; NED, no evidence of disease; ROD, recurrence of disease; DOD, dead of disease; NA, not available; mo, months.